Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iferanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | MMP1 | P03956 | 5/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.46 |
| ▸ | MMP9 | P14780 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iferanserin SCHEMBL659141 | 1.00 | DRD1 (0.61) | DRD1HRH2HTR2AHTR2COPRK1 | |
| Iferanserin SCHEMBL658305 | 0.99 | DRD1 (0.62) | DRD1HRH2HTR2AHTR2COPRK1 | |
| Iferanserin SCHEMBL4121794 | 0.99 | DRD1 (0.62) | DRD1HRH2HTR2AHTR2COPRK1 | |
| Iferanserin SCHEMBL658304 | 0.99 | DRD1 (0.62) | DRD1HRH2HTR2AHTR2COPRK1 | |
| SCHEMBL11321421 | 0.93 | HTR2A (0.55) | DRD1HRH2HTR2AHTR2COPRK1 | |
| SCHEMBL10001072 | 0.92 | DRD1 (0.59) | DRD1HRH2HTR2AHTR2COPRK1 | |
| SCHEMBL11329889 | 0.88 | DRD1 (0.48) | DRD1HRH2HTR2AHTR2COPRK1 | |
| SCHEMBL11331432 | 0.87 | DRD1 (0.60) | DRD1HRH2HTR2AHTR2COPRK1 | |
| SCHEMBL10001071 | 0.85 | KDM1A (0.58) | DRD1HRH2HTR2AHTR2COPRK1 | |
| Hydrochloric Acid SCHEMBL11322983 | 0.83 | CYSLTR2 (0.44) | DRD1HRH2HTR2AHTR2COPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046318-A1 | METHODS AND COMPOSITIONS FOR TREATING INTERNAL AND EXTERNAL HEMORRHOIDS | VENTRUS BIOSCIENCES, INC. | 2012-02-23 | — | — | US | claimed |
| EP-0684816-B1 | 5-HT2 RECEPTOR ANTAGONISTS FOR TREATING VENOUS CONDITIONS | SAM AMER & CO INC (US) | 2004-02-04 | — | — | EP | claimed |
| US-5605902-A | ADMINISTERING TO TREAT OR PREVENT VARICOSE VEINS OR VENOUS INSUFFIENCY OR TO TREAT WOUNDS | SAM AMER & CO. (US) | 1997-02-25 | — | — | US | claimed |
| US-5266571-A | Treatment of hemorrhoids with 5-HT2 antagonists | VENTRUS BIOSCIENCES, INC. | 1993-11-30 | — | — | US | claimed |
| US-RE30812-E | ANTIARRHTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | claimed |
| US-RE30811-E | SEROTONIN ANTAGONISTS, ANTIARRHYTHMIA AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-01 | — | — | US | claimed |
| US-4064254-A | ANTIARRHYTHMIC AND ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1977-12-20 | — | — | US | claimed |
| US-3931195-A | ANTIARRHYTHMIA, ANTISEROTONIN | MEAD JOHNSON & COMPANY (US) | 1976-01-06 | — | — | US | claimed |
| WO-2013070236-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMORRHOIDS WHILE PROVIDING LOCAL ANESTHETIC AND ANTI-INFLAMMATORY EFFECTS | VENTRUS BIOSCIENCES, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012026914-A1 | METHODS AND COMPOSITIONS FOR TREATING INTERNAL AND EXTERNAL HEMORRHOIDS | SAM AMER & CO., INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20120046318-A1 | METHODS AND COMPOSITIONS FOR TREATING INTERNAL AND EXTERNAL HEMORRHOIDS | VENTRUS BIOSCIENCES, INC. | 2012-02-23 | — | — | US | disclosed |
| EP-0684816-B1 | 5-HT2 RECEPTOR ANTAGONISTS FOR TREATING VENOUS CONDITIONS | SAM AMER & CO INC (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-0973741-B1 | S-2'-(2-(1-METHYL-2-PIPERIDYL) ETHYL) CINNAMANILIDE AS A 5-HT2 RECEPTOR ANTAGONIST | AMER M SAMIR (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-0973741-A1 | S-2'-(2-(1-METHYL-2-PIPERIDYL) ETHYL) CINNAMANILIDE AS A 5-HT2 RECEPTOR ANTAGONIST | AMER, M. Samir (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998038165-A1 | S-2'-(2-(1-METHYL-2-PIPERIDYL) ETHYL) CINNAMANILIDE AS A 5-HT2 RECEPTOR ANTAGONIST | AMER MOH SAMIR (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5605902-A | ADMINISTERING TO TREAT OR PREVENT VARICOSE VEINS OR VENOUS INSUFFIENCY OR TO TREAT WOUNDS | SAM AMER & CO. (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0684816-A1 | 5-HT 2? RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | SAM AMER & CO., INC. (US) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018958-A1 | 5-HT2 RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | SAM AMER & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5266571-A | Treatment of hemorrhoids with 5-HT2 antagonists | VENTRUS BIOSCIENCES, INC. | 1993-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046318-A1 | METHODS AND COMPOSITIONS FOR TREATING INTERNAL AND EXTERNAL HEMORRHOIDS | APC, P4HA1, EGLN2 | HTR2A 674/4885DRD1 2573/4885HRH2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.